thalidomide has been researched along with Plasmacytoma in 49 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Plasmacytoma: Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In conclusion, pomalidomide and dexamethasone has limited efficacy in patients with advanced MM and soft-tissue plasmacytomas." | 7.91 | Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma. ( Abella, E; Bladé, J; Cabezudo, E; Cibeira, MT; Clapés, V; Escoda, L; Fernández de Larrea, C; García-Guiñón, A; Gironella, M; Granell, M; Isola, I; Jiménez-Segura, R; López-Pardo, J; Oriol, A; Rosiñol, L; Soler, JA; Tovar, N, 2019) |
| "Thalidomide and its analogs have been extensively studied in patients with multiple myeloma." | 7.73 | Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide. ( Carbonell, AL; del Giglio, A; Manhani, AR; Mitteldorf, CA; Weinschenker, P, 2005) |
| "Thalidomide (Thd), a potent teratogen, was shown to have therapeutic potential in cancer, primarily in multiple myeloma (MM), yet its mechanism of action has not been elucidated." | 7.72 | Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma. ( Drucker, L; Lahav, M; Lishner, M; Radnay, J; Shapiro, H; Tohami, T; Uziel, O; Yarkoni, S, 2003) |
| "We report two patients who were treated with thalidomide for resistant multiple myeloma (MM) and developed extramedullary plasmacytomas despite a good response in the bone marrow." | 7.71 | Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. ( Avigdor, A; Ben-Bassat, I; Hardan, I; Levi, I; Raanani, P, 2001) |
| "The pathogenesis of POEMS syndrome is not well understood, but overproduction of vascular endothelial growth factor (VEGF), probably secreted by plasmacytoma, may be responsible for most of its characteristic symptoms." | 6.44 | [New strategy of treatment for POEMS syndrome--autologous peripheral blood stem cell transplantation and thalidomide therapy]. ( Kuwabara, S, 2008) |
| "Intracerebral plasmacytoma is an extremely rare disease for which no treatment protocol has been established." | 5.46 | Metastatic Intracerebral Plasmacytoma Treated with Radiation and Thalidomide, Dexamethasone with Cyclophosphamide Chemotherapy. ( Kang, SH; Kim, TS; Ko, SJ; Park, KJ, 2017) |
| "A 74-year-old man with multiple myeloma was refractory to melphalan/prednisolone (MP), high-dose dexamethasone and VAD chemotherapy." | 5.35 | Refractory plasmablastic type myeloma with multiple extramedullary plasmacytomas and massive myelomatous effusion: remarkable response with a combination of thalidomide and dexamethasone. ( Kakimoto, T; Mihara, A; Nakazato, T; Sanada, Y; Suzuki, K, 2009) |
| "Thalidomide has antiangiogenic and immunomodulatory effects, mediated by several cytokines such as vascular endothelial growth factor (VEGF), fibroblastic growth factor (FGF-2), hepatocyte growth factor (HGF), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha)." | 5.32 | Response to thalidomide in multiple myeloma: impact of angiogenic factors. ( Arenillas, L; Aymerich, M; Bladé, J; Cibeira, MT; Cid, MC; Esteve, J; Filella, X; Montserrat, E; Rosiñol, L; Rozman, M; Segarra, M, 2004) |
| " The tandem transplant trial, Total Therapy 2, enrolled 668 patients, who were randomised up-front to thalidomide (THAL) or no THAL; 56 patients were identified as having had, for at least 6 months prior to initiation of therapy, monoclonal gammopathy of undetermined significance (MGUS, n = 21), smouldering MM (SMM, n = 22) or solitary plasmacytoma of bone (SPC, n = 13)." | 5.12 | Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. ( Anaissie, E; Arzoumanian, V; Barlogie, B; Bolejack, V; Crowley, J; Epstein, J; Hollmig, K; Krishna, S; Pineda-Roman, M; Shaughnessy, JD; van Rhee, F; Walker, R; Zangari, M, 2007) |
| "In conclusion, pomalidomide and dexamethasone has limited efficacy in patients with advanced MM and soft-tissue plasmacytomas." | 3.91 | Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma. ( Abella, E; Bladé, J; Cabezudo, E; Cibeira, MT; Clapés, V; Escoda, L; Fernández de Larrea, C; García-Guiñón, A; Gironella, M; Granell, M; Isola, I; Jiménez-Segura, R; López-Pardo, J; Oriol, A; Rosiñol, L; Soler, JA; Tovar, N, 2019) |
| "Patients with complicated extramedullary plasmacytomas at the time of diagnosis received traditional treatment, including vincristine adriamycin, dexamethasone, medphalan, prednisone, thalidomide and bortezomib." | 3.75 | [A clinical analysis of 25 cases of multiple myeloma complicated by extramedullary plasmacytomas]. ( Chen, SL; Zhong, YP, 2009) |
| "Thalidomide and its analogs have been extensively studied in patients with multiple myeloma." | 3.73 | Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide. ( Carbonell, AL; del Giglio, A; Manhani, AR; Mitteldorf, CA; Weinschenker, P, 2005) |
| "Thalidomide (Thd), a potent teratogen, was shown to have therapeutic potential in cancer, primarily in multiple myeloma (MM), yet its mechanism of action has not been elucidated." | 3.72 | Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma. ( Drucker, L; Lahav, M; Lishner, M; Radnay, J; Shapiro, H; Tohami, T; Uziel, O; Yarkoni, S, 2003) |
| "We report two patients who were treated with thalidomide for resistant multiple myeloma (MM) and developed extramedullary plasmacytomas despite a good response in the bone marrow." | 3.71 | Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. ( Avigdor, A; Ben-Bassat, I; Hardan, I; Levi, I; Raanani, P, 2001) |
| "Acquired hemophilia A is a rare autoimmune disease with clinically often significant bleeding diathesis resulting from circulating autoantibodies inhibiting coagulation factor VIII." | 2.66 | Acquired hemophilia A and plasma cell neoplasms: a case report and review of the literature. ( Andres, M; Angelillo-Scherrer, A; Dickenmann, M; Jalowiec, KA; Kremer Hovinga, JA; Musa, A; Rovó, A; Taleghani, BM, 2020) |
| "Primary plasmacytomas are localized proliferations of clonal plasma cells occurring in the absence of a systemic plasma cell dyscrasia such as multiple myeloma." | 2.61 | Primary extramedullary plasmacytoma with diffuse lymph node involvement: a case report and review of the literature. ( Abdul-Hay, M; Naymagon, L, 2019) |
| "The pathogenesis of POEMS syndrome is not well understood; however overproduction of vascular endothelial growth factor (VEGF), probably secreted by plasmacytoma, may be responsible for most of the characteristic symptoms, including neuropathy." | 2.44 | [Electrophysiologic aspects of Crow-Fukase (POEMS) syndrome--significance in early diagnosis and insights into the pathophysiology]. ( Misawa, S, 2008) |
| "The pathogenesis of POEMS syndrome is not well understood, but overproduction of vascular endothelial growth factor (VEGF), probably secreted by plasmacytoma, may be responsible for most of its characteristic symptoms." | 2.44 | [New strategy of treatment for POEMS syndrome--autologous peripheral blood stem cell transplantation and thalidomide therapy]. ( Kuwabara, S, 2008) |
| "Intracerebral plasmacytoma is an extremely rare disease for which no treatment protocol has been established." | 1.46 | Metastatic Intracerebral Plasmacytoma Treated with Radiation and Thalidomide, Dexamethasone with Cyclophosphamide Chemotherapy. ( Kang, SH; Kim, TS; Ko, SJ; Park, KJ, 2017) |
| "Progression to multiple myeloma is the most common pattern of relapse." | 1.46 | Metachronous solitary plasmacytoma. ( Khosa, R; Nangia, S; Seth, S, 2017) |
| "Plasmacytomas are monoclonal plasma cell tumors." | 1.42 | Diplopia and variable ptosis as the sole initial findings in a case of orbital plasmacytoma and multiple myeloma. ( Galea, M; McMillan, N; Weir, C, 2015) |
| " Xenografts acquired resistance to two generations of immunomodulatory drugs (IMiDs; lenalidomide and pomalidomide) in combination with dexamethasone, that was reversible after a wash-out period." | 1.42 | In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. ( Bjorklund, CC; Corchete, LA; Couto, S; Delgado, M; Díaz-Rodríguez, E; Fernández-Lázaro, D; Garayoa, M; García-Gómez, A; Gutiérrez, NC; López-Corral, L; Mateos, MV; Montero, JC; Ocio, EM; Paíno, T; Pandiella, A; San-Miguel, JF; San-Segundo, L; Wang, M, 2015) |
| "The patient was diagnosed with multiple myeloma and received chemotherapy with thalidomide, cyclophosphamide and dexamethasone." | 1.39 | Multiple myeloma presenting as plasmacytoma of the jaws showing prominent bone formation during chemotherapy. ( An, CH; An, SY; Choi, KS; Heo, MS, 2013) |
| "Plasmacytoma is a rare B-lymphocyte neoplastic disorder that usually presents as the generalized disease multiple myeloma." | 1.36 | Solitary extramedullary plasmacytoma of the bladder: a case report and literature. ( Egner, JR; Khaliq, W; Konchanin, RP; Sapiente, RA; Uzoaru, I, 2010) |
| "Cranial nerve involvement in multiple myeloma and solitary plasmacytoma is rare." | 1.36 | Cranial nerve palsy in multiple myeloma and solitary plasmacytoma. ( Kashyap, R; Kumar, R; Kumar, S, 2010) |
| "A 74-year-old man with multiple myeloma was refractory to melphalan/prednisolone (MP), high-dose dexamethasone and VAD chemotherapy." | 1.35 | Refractory plasmablastic type myeloma with multiple extramedullary plasmacytomas and massive myelomatous effusion: remarkable response with a combination of thalidomide and dexamethasone. ( Kakimoto, T; Mihara, A; Nakazato, T; Sanada, Y; Suzuki, K, 2009) |
| "These cases of unconventional disease recurrence are likely to be seen due to sub-clinical seeding of tumour cells suggestive of the presence of an extramedullary (EM) clone of plasma cells with a high degree of chemoresistance." | 1.33 | Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. ( Apperley, JF; Basu, S; Milne, AE; Rahemtulla, A; Rezvani, K; Rose, PE; Samson, D; Scott, GL; Terpos, E, 2005) |
| "Thalidomide has antiangiogenic and immunomodulatory effects, mediated by several cytokines such as vascular endothelial growth factor (VEGF), fibroblastic growth factor (FGF-2), hepatocyte growth factor (HGF), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha)." | 1.32 | Response to thalidomide in multiple myeloma: impact of angiogenic factors. ( Arenillas, L; Aymerich, M; Bladé, J; Cibeira, MT; Cid, MC; Esteve, J; Filella, X; Montserrat, E; Rosiñol, L; Rozman, M; Segarra, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (38.78) | 29.6817 |
| 2010's | 25 (51.02) | 24.3611 |
| 2020's | 5 (10.20) | 2.80 |
| Authors | Studies |
|---|---|
| Oyama, T | 1 |
| Taoka, K | 1 |
| Chiba, A | 1 |
| Masamoto, Y | 1 |
| Ikemura, M | 1 |
| Honda, A | 1 |
| Maki, H | 1 |
| Kurokawa, M | 1 |
| Lin, Y | 1 |
| He, J | 1 |
| Li, F | 1 |
| Gu, X | 1 |
| Oka, S | 1 |
| Ono, K | 1 |
| Nohgawa, M | 1 |
| Mouhieddine, TH | 1 |
| Barlogie, B | 2 |
| Teruya-Feldstein, J | 1 |
| Jalowiec, KA | 1 |
| Andres, M | 1 |
| Taleghani, BM | 1 |
| Musa, A | 1 |
| Dickenmann, M | 1 |
| Angelillo-Scherrer, A | 1 |
| Rovó, A | 1 |
| Kremer Hovinga, JA | 1 |
| Kim, TS | 1 |
| Ko, SJ | 1 |
| Park, KJ | 1 |
| Kang, SH | 1 |
| Al-Mayoof, O | 1 |
| Al Sughaiyer, H | 1 |
| Abuomar, W | 1 |
| Khan, M | 1 |
| Khosa, R | 1 |
| Seth, S | 1 |
| Nangia, S | 1 |
| Quilodrán, JA | 1 |
| Peña, C | 1 |
| Valladares, X | 1 |
| de Assis Pereira Hansen, C | 1 |
| Filho, JS | 1 |
| de Mattos Nascimento, M | 1 |
| Alves, FA | 1 |
| Neotti, T | 1 |
| D Almeida Costa, F | 1 |
| Jiménez-Segura, R | 1 |
| Granell, M | 1 |
| Gironella, M | 1 |
| Abella, E | 1 |
| García-Guiñón, A | 1 |
| Oriol, A | 1 |
| Cabezudo, E | 1 |
| Clapés, V | 1 |
| Soler, JA | 1 |
| Escoda, L | 1 |
| López-Pardo, J | 1 |
| Fernández de Larrea, C | 1 |
| Cibeira, MT | 2 |
| Tovar, N | 1 |
| Isola, I | 1 |
| Bladé, J | 3 |
| Rosiñol, L | 3 |
| Naymagon, L | 1 |
| Abdul-Hay, M | 1 |
| An, SY | 1 |
| An, CH | 1 |
| Choi, KS | 1 |
| Heo, MS | 1 |
| Sekiguchi, Y | 1 |
| Asahina, T | 1 |
| Shimada, A | 1 |
| Imai, H | 1 |
| Wakabayashi, M | 1 |
| Sugimoto, K | 1 |
| Nakamura, N | 1 |
| Sawada, T | 1 |
| Komatsu, N | 1 |
| Noguchi, M | 1 |
| Smith, D | 1 |
| Stevens, J | 1 |
| Quinn, J | 1 |
| Cavenagh, J | 1 |
| Ingram, W | 1 |
| Yong, K | 1 |
| Galea, M | 1 |
| McMillan, N | 1 |
| Weir, C | 1 |
| Devoe, CE | 1 |
| Li, JY | 1 |
| Demopoulos, AM | 1 |
| Sharman, JP | 1 |
| Chmielecki, J | 1 |
| Morosini, D | 1 |
| Palmer, GA | 1 |
| Ross, JS | 1 |
| Stephens, PJ | 1 |
| Stafl, J | 1 |
| Miller, VA | 1 |
| Ali, SM | 1 |
| Ocio, EM | 1 |
| Fernández-Lázaro, D | 1 |
| San-Segundo, L | 1 |
| López-Corral, L | 1 |
| Corchete, LA | 1 |
| Gutiérrez, NC | 1 |
| Garayoa, M | 1 |
| Paíno, T | 1 |
| García-Gómez, A | 1 |
| Delgado, M | 1 |
| Montero, JC | 1 |
| Díaz-Rodríguez, E | 1 |
| Mateos, MV | 1 |
| Pandiella, A | 1 |
| Couto, S | 1 |
| Wang, M | 1 |
| Bjorklund, CC | 1 |
| San-Miguel, JF | 1 |
| Varga, C | 1 |
| Xie, W | 1 |
| Laubach, J | 1 |
| Ghobrial, IM | 1 |
| O'Donnell, EK | 1 |
| Weinstock, M | 1 |
| Paba-Prada, C | 1 |
| Warren, D | 1 |
| Maglio, ME | 1 |
| Schlossman, R | 1 |
| Munshi, NC | 1 |
| Raje, N | 1 |
| Weller, E | 1 |
| Anderson, KC | 1 |
| Mitsiades, CS | 1 |
| Richardson, PG | 1 |
| Salem, KZ | 1 |
| Nishihori, T | 1 |
| Kharfan-Dabaja, MA | 1 |
| Horna, P | 1 |
| Alsina, M | 1 |
| Aagre, S | 1 |
| Madabhavi, I | 1 |
| Patel, A | 1 |
| Anand, A | 1 |
| Panchal, H | 1 |
| Parikh, S | 1 |
| Misawa, S | 1 |
| Kuwabara, S | 1 |
| Zhong, YP | 1 |
| Chen, SL | 1 |
| Nakazato, T | 2 |
| Suzuki, K | 1 |
| Mihara, A | 2 |
| Sanada, Y | 2 |
| Kakimoto, T | 1 |
| Ninan, MJ | 1 |
| Datta, YH | 1 |
| Khaliq, W | 1 |
| Uzoaru, I | 1 |
| Konchanin, RP | 1 |
| Sapiente, RA | 1 |
| Egner, JR | 1 |
| Wilson, SS | 1 |
| Theodorescu, D | 1 |
| Kashyap, R | 1 |
| Kumar, R | 1 |
| Kumar, S | 1 |
| Grape, J | 1 |
| Frosch, P | 1 |
| Ito, C | 1 |
| Aisa, Y | 1 |
| Fukushima, T | 1 |
| Nakamura, T | 1 |
| Iwao, H | 1 |
| Umehara, H | 1 |
| Kawada, H | 1 |
| Arima, N | 1 |
| Drucker, L | 1 |
| Uziel, O | 1 |
| Tohami, T | 1 |
| Shapiro, H | 1 |
| Radnay, J | 1 |
| Yarkoni, S | 1 |
| Lahav, M | 1 |
| Lishner, M | 1 |
| Cisteró, B | 1 |
| Sala, M | 1 |
| Soler, A | 1 |
| García, N | 1 |
| Segarra, M | 1 |
| Cid, MC | 1 |
| Filella, X | 1 |
| Aymerich, M | 1 |
| Rozman, M | 1 |
| Arenillas, L | 1 |
| Esteve, J | 2 |
| Montserrat, E | 2 |
| Ribas, C | 1 |
| Colleoni, G | 1 |
| Almeida, M | 1 |
| Duch, CR | 1 |
| Ohashi, C | 1 |
| Segreto, R | 1 |
| Silva, MR | 1 |
| del Giglio, A | 1 |
| Weinschenker, P | 1 |
| Manhani, AR | 1 |
| Carbonell, AL | 1 |
| Mitteldorf, CA | 1 |
| Gaur, S | 1 |
| Oo, TH | 1 |
| Aish, LS | 1 |
| Mansoor, S | 1 |
| Terpos, E | 2 |
| Rezvani, K | 1 |
| Basu, S | 1 |
| Milne, AE | 1 |
| Rose, PE | 1 |
| Scott, GL | 1 |
| Rahemtulla, A | 1 |
| Samson, D | 1 |
| Apperley, JF | 1 |
| Terrier, B | 1 |
| Aouba, A | 1 |
| Diop, S | 1 |
| Clerc, J | 1 |
| Vasiliu, V | 1 |
| Munera, Y | 1 |
| Hermine, O | 1 |
| Katodritou, E | 1 |
| Speletas, M | 1 |
| Pouli, A | 1 |
| Tsitouridis, J | 1 |
| Zervas, K | 1 |
| Pineda-Roman, M | 1 |
| Bolejack, V | 1 |
| Arzoumanian, V | 1 |
| Anaissie, E | 1 |
| van Rhee, F | 1 |
| Zangari, M | 1 |
| Walker, R | 1 |
| Hollmig, K | 1 |
| Shaughnessy, JD | 1 |
| Epstein, J | 1 |
| Krishna, S | 1 |
| Crowley, J | 1 |
| Patil, S | 1 |
| Schwarer, A | 1 |
| McLean, C | 1 |
| Dytfeld, D | 1 |
| Matuszak, M | 1 |
| Lewandowski, K | 1 |
| Komarnicki, M | 1 |
| Perales, M | 1 |
| Tuset, M | 1 |
| Montoto, S | 1 |
| Cobo, F | 1 |
| Villela, L | 1 |
| Rafel, M | 1 |
| Nomdedeu, B | 1 |
| Avigdor, A | 1 |
| Raanani, P | 1 |
| Levi, I | 1 |
| Hardan, I | 1 |
| Ben-Bassat, I | 1 |
| Myers, B | 1 |
| Grimley, C | 1 |
| Crouch, D | 1 |
| Dolan, G | 1 |
8 reviews available for thalidomide and Plasmacytoma
| Article | Year |
|---|---|
Acquired hemophilia A and plasma cell neoplasms: a case report and review of the literature.
Topics: Aged; Factor VIII; Hemophilia A; Humans; Lenalidomide; Male; Multiple Myeloma; Plasmacytoma; Thalido | 2020 |
Primary extramedullary plasmacytoma with diffuse lymph node involvement: a case report and review of the literature.
Topics: Aged; Bortezomib; Dexamethasone; Fatigue; Humans; Lymph Nodes; Lymphadenopathy; Male; Plasma Cells; | 2019 |
A case of extramedullary plasmablastic plasmacytoma successfully treated using a combination of thalidomide and dexamethasone and a review of the medical literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Male; Middle Aged; Multiple M | 2013 |
[Electrophysiologic aspects of Crow-Fukase (POEMS) syndrome--significance in early diagnosis and insights into the pathophysiology].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Dia | 2008 |
[New strategy of treatment for POEMS syndrome--autologous peripheral blood stem cell transplantation and thalidomide therapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Com | 2008 |
Post-transplant lymphoproliferative disorder presenting as multiple myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
Rare bladder tumors: caveat emptor.
Topics: Abnormalities, Drug-Induced; Disease Progression; Female; Humans; Lenalidomide; Male; Multiple Myelo | 2010 |
[Update on treatment of multiple myeloma: including myeloma kidney and molecular targeting drugs].
Topics: Boronic Acids; Bortezomib; Drug Design; Humans; Immunologic Factors; Kidney Neoplasms; Lenalidomide; | 2012 |
1 trial available for thalidomide and Plasmacytoma
| Article | Year |
|---|---|
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease.
Topics: Aged; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Moda | 2007 |
40 other studies available for thalidomide and Plasmacytoma
| Article | Year |
|---|---|
Daratumumab plus lenalidomide and dexamethasone for relapsed POEMS syndrome with bone plasmacytoma harboring 17p deletion.
Topics: Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Plasmacytoma; PO | 2023 |
Rare Pattern of Myelodysplastic Syndrome (MDS) with Serum Monoclonal Immunoglobulin: Case Report.
Topics: Danazol; Dexamethasone; Humans; Male; Myelodysplastic Syndromes; Plasmacytoma; Thalidomide | 2023 |
Successful treatment with pomalidomide and intrathecal injections for central nervous system plasmacytoma in a patient under haemodialysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophospha | 2020 |
Hemophagocytic relapsed intramedullary plasmacytoma.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bo | 2020 |
Metastatic Intracerebral Plasmacytoma Treated with Radiation and Thalidomide, Dexamethasone with Cyclophosphamide Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cranial Irradiation; Cyclophosphami | 2017 |
POEMS syndrome: a rare cause of exudative ascites and chronic peripheral neuropathy.
Topics: Adult; Ascites; Dexamethasone; Humans; Lenalidomide; Male; Myeloma Proteins; Paraproteinemias; Perip | 2017 |
Metachronous solitary plasmacytoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Diphosphonates; Di | 2017 |
[Extramedullary mediastinal plasmacytoma. Report of one case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Mediastinal Neoplasms; Mediastin | 2017 |
Extramedullary Manifestation of Multiple Myeloma in the Oral Cavity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; Fata | 2018 |
Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplas | 2019 |
Multiple myeloma presenting as plasmacytoma of the jaws showing prominent bone formation during chemotherapy.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; A | 2013 |
Myeloma presenting during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; | 2014 |
Diplopia and variable ptosis as the sole initial findings in a case of orbital plasmacytoma and multiple myeloma.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Blepharoptosis; Bone Marrow Cells; Cyclophosphamide; Dexa | 2015 |
The successful treatment of a recurrent intracranial, dural-based plasmacytoma with lenalidomide.
Topics: Aged; Angiogenesis Inhibitors; Brain Neoplasms; Female; Humans; Lenalidomide; Neoplasm Recurrence, L | 2014 |
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2014 |
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Cel | 2015 |
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Female; Foll | 2015 |
Primary plasmacytoma involving mediastinal lymph nodes: A diagnostic mimicry of primary mediastinal lymphoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Humans; Lenalidomide; Lymph Nodes; Male; | 2016 |
Primary Plurifocal Extramedullary Plasmacytoma of Breast.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Breast Neoplasms; Dexamethasone; | 2016 |
[A clinical analysis of 25 cases of multiple myeloma complicated by extramedullary plasmacytomas].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2009 |
Refractory plasmablastic type myeloma with multiple extramedullary plasmacytomas and massive myelomatous effusion: remarkable response with a combination of thalidomide and dexamethasone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Male; Multiple Myeloma; | 2009 |
Solitary extramedullary plasmacytoma of the bladder: a case report and literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cystoscopy; Dexamethasone; Humans; Len | 2010 |
Cranial nerve palsy in multiple myeloma and solitary plasmacytoma.
Topics: Abducens Nerve Diseases; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2010 |
[Papular drug eruption along the lines of Blaschko caused by lenalidomide].
Topics: Antineoplastic Agents; Diagnosis, Differential; Drug Eruptions; Humans; Leg Dermatoses; Lenalidomide | 2011 |
Lenalidomide is active for extramedullary disease in refractory multiple myeloma.
Topics: Aged, 80 and over; Antineoplastic Agents; Humans; Lenalidomide; Male; Multiple Myeloma; Plasmacytoma | 2012 |
Rapid response of plasmacytomas to lenalidomide plus low-dose dexamethasone therapy in a patient with relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Middle | 2011 |
Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma.
Topics: Adenomatous Polyposis Coli Protein; Antigens, CD; DNA-Binding Proteins; GC Rich Sequence; Humans; Im | 2003 |
[Thalidomide in the treatment of recurrent plasmocitomas in an HIV-infected patient].
Topics: HIV Infections; Humans; Male; Middle Aged; Plasmacytoma; Recurrence; Thalidomide | 2004 |
Response to thalidomide in multiple myeloma: impact of angiogenic factors.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Angiogenic Proteins; Cytokines; Female; Human | 2004 |
Response of plasmacytomas to low-dose thalidomide in a patient with refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Humans; Male; Mandibular Neoplasms; Middle Aged; Multiple Myeloma; Plasmacy | 2004 |
Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
Topics: Antineoplastic Agents; Asthenia; Biopsy; Bone Marrow Cells; Boronic Acids; Bortezomib; Female; Human | 2005 |
Gastric relapse of solitary bone plasmacytoma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combin | 2005 |
Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clone Cells; Disease Progression; Dose-Respons | 2005 |
Thyroid gland plasmacytoma with a dramatic and persistent complete response under thalidomide and dexamethasone-associated treatment.
Topics: Aged; Antineoplastic Agents, Hormonal; Dexamethasone; Female; Humans; Immunosuppressive Agents; Mult | 2006 |
Successful treatment of extramedullary plasmacytoma of the cavernous sinus using a combination of intermediate dose of thalidomide and dexamethasone.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cavernous Sinus; Dexamethas | 2007 |
Urinary cytology in multiple myeloma.
Topics: Acute Kidney Injury; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Fat | 2008 |
Bortezomib in combination with thalidomide and dexamethasone--a successful treatment regimen in refractory extramedullary multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Ma | 2008 |
Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas.
Topics: Aged; Bone Marrow Cells; Connectin; Drug Administration Schedule; Female; Humans; Immunosuppressive | 2001 |
Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma.
Topics: Adult; Bone Marrow; Bone Marrow Neoplasms; Brain Neoplasms; Disease Progression; Humans; Male; Middl | 2001 |
Lack of response to thalidomide in plasmacytomas.
Topics: Humans; Immunosuppressive Agents; Male; Middle Aged; Paraproteins; Plasmacytoma; Thalidomide; Treatm | 2001 |